An Excess of CYP24A1, Lack of CaSR, and a Novel lncRNA Near the PTH Gene Characterize an Ectopic PTH-Producing Tumor

Thus far, only 23 cases of the ectopic production of parathyroid hormone (PTH) have been reported. We have characterized the genome-wide transcription profile of an ectopic PTH-producing tumor originating from a retroperitoneal histiocytoma. We found that the calcium-sensing receptor (CaSR) was barely expressed in the tumor. Lack of CaSR, a crucial braking apparatus in the presence of both intraparathyroid and, probably, serendipitous PTH expression, might contribute strongly to the establishment and maintenance of the ectopic transcriptional activation of the PTH gene in nonparathyroid cells. Along with candidate drivers with a crucial frameshift mutation or copy number variation at specific chromosomal areas obtained from whole exome sequencing, we identified robust tumor-specific cytochrome P450 family 24 subfamily A member 1 (CYP24A1) overproduction, which was not observed in other non–PTH-expressing retroperitoneal histiocytoma and parathyroid adenoma samples. We then found a 2.5-kb noncoding RNA in the PTH 3′-downstream region that was exclusively present in the parathyroid adenoma and our tumor. Such a co-occurrence might act as another driver of ectopic PTH-producing tumorigenesis; both might release the control of PTH gene expression by shutting down the other branches of the safety system (e.g., CaSR and the vitamin D3–vitamin D receptor axis).

[1]  E. Kallay,et al.  Cross Talk between the Calcium-Sensing Receptor and the Vitamin D System in Prevention of Cancer , 2016, Front. Physiol..

[2]  Thai D. Nguyen,et al.  Disruption of Vitamin D and Calcium Signaling in Keratinocytes Predisposes to Skin Cancer , 2016, Front. Physiol..

[3]  T. Martin,et al.  Parathyroid Hormone-Related Protein, Its Regulation of Cartilage and Bone Development, and Role in Treating Bone Diseases. , 2016, Physiological reviews.

[4]  G. Westin Molecular genetics and epigenetics of nonfamilial (sporadic) parathyroid tumours , 2016, Journal of internal medicine.

[5]  K. Shim,et al.  Significance of calcium-sensing receptor expression in gastric cancer , 2016, Scandinavian journal of gastroenterology.

[6]  Maite Huarte The emerging role of lncRNAs in cancer , 2015, Nature Medicine.

[7]  N. Suh,et al.  Targeting cancer stem cells in solid tumors by vitamin D , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  Anton J. Enright,et al.  Quantitative gene profiling of long noncoding RNAs with targeted RNA sequencing , 2015, Nature Methods.

[9]  H. Lodish,et al.  Long non-coding RNAs as regulators of the endocrine system , 2015, Nature Reviews Endocrinology.

[10]  Alexander Pertsemlidis,et al.  Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling. , 2015, Cancer research.

[11]  T. Nakakura,et al.  Marked Cortisol Production by Intracrine ACTH in GIP-Treated Cultured Adrenal Cells in Which the GIP Receptor Was Exogenously Introduced , 2014, PloS one.

[12]  Atsushi Tanaka,et al.  Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma , 2014, Nature Genetics.

[13]  A. Fatica,et al.  Long non-coding RNAs: new players in cell differentiation and development , 2013, Nature Reviews Genetics.

[14]  B. Lanske,et al.  Parathyroid-Specific Deletion of Klotho Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion , 2013, PLoS genetics.

[15]  P. Hershberger,et al.  24-Hydroxylase in cancer: Impact on vitamin D-based anticancer therapeutics , 2013, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  F. Bruggeman,et al.  Calcium sensing receptor signalling in physiology and cancer. , 2013, Biochimica et biophysica acta.

[17]  A. Arnold,et al.  Germline and Somatic Mutations in Cyclin-Dependent Kinase Inhibitor Genes CDKN1A, CDKN2B, and CDKN2C in Sporadic Parathyroid Adenomas , 2013, Hormones and Cancer.

[18]  K. Nakajima,et al.  Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature. , 2013, Endocrine journal.

[19]  Murim Choi,et al.  Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. , 2012, The Journal of clinical endocrinology and metabolism.

[20]  G. Åkerström,et al.  Hypermethylated in cancer 1 (HIC1), a tumour suppressor gene epigenetically deregulated in hyperparathyroid tumours by histone modification , 2012 .

[21]  G. Åkerström,et al.  Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification. , 2012, The Journal of clinical endocrinology and metabolism.

[22]  C. Larsson,et al.  Genetic characterization of large parathyroid adenomas , 2012, Endocrine-related cancer.

[23]  E. Kallay,et al.  Colonic vitamin D metabolism: Implications for the pathogenesis of inflammatory bowel disease and colorectal cancer , 2011, Molecular and Cellular Endocrinology.

[24]  I. Grigorieva,et al.  Transcription factors in parathyroid development: lessons from hypoparathyroid disorders , 2011, Annals of the New York Academy of Sciences.

[25]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[26]  R. Mantovani,et al.  NF-Y is essential for expression of the proapoptotic bim gene in sympathetic neurons , 2011, Cell Death and Differentiation.

[27]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[28]  G. Bernini,et al.  A case of pheochromocytoma presenting as secondary hyperaldosteronism, hyperparathyroidism, diabetes and proteinuric renal disease. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  A. Arnold,et al.  Tissue‐specific regulatory regions of the PTH gene localized by novel chromosome 11 rearrangement breakpoints in a parathyroid adenoma , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  T. Naveh-Many Minireview: the play of proteins on the parathyroid hormone messenger ribonucleic Acid regulates its expression. , 2010, Endocrinology.

[31]  R. Hannan,et al.  ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. , 2010, Genome research.

[32]  P. Hershberger,et al.  The Candidate Oncogene CYP24A1: A Potential Biomarker for Colorectal Tumorigenesis , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[33]  D. Beer,et al.  The vitamin D/CYP24A1 story in cancer. , 2010, Anti-cancer agents in medicinal chemistry.

[34]  S. Libutti,et al.  Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. , 2009, American journal of physiology. Renal physiology.

[35]  T. Uchida,et al.  The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism. , 2009, The Journal of clinical investigation.

[36]  A. Haque,et al.  Small cell carcinoma of the ovary with hypercalcemia and ectopic parathyroid hormone production. , 2009, Archives of pathology & laboratory medicine.

[37]  J. Silver,et al.  Human PTH gene regulation in vivo using transgenic mice. , 2009, American journal of physiology. Renal physiology.

[38]  D. Stephan,et al.  Scavenger Chemokine (CXC Motif) Receptor 7 (CXCR7) Is a Direct Target Gene of HIC1 (Hypermethylated in Cancer 1)* , 2009, The Journal of Biological Chemistry.

[39]  D. Clark,et al.  An unusual case of recurrent hyperparathyroidism and papillary thyroid cancer. , 2009, Endocrine Practice.

[40]  J. Richardson,et al.  Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma. , 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[41]  C. Morrison,et al.  Chromosome 11 genomic changes in parathyroid adenoma and hyperplasia: Array CGH, FISH, and tissue microarrays , 2008, Genes, chromosomes & cancer.

[42]  G. Mundy,et al.  PTH-related peptide (PTHrP) in hypercalcemia. , 2008, Journal of the American Society of Nephrology : JASN.

[43]  S. Silverberg Vitamin D Deficiency and Primary Hyperparathyroidism , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  Tsutomu Ohta,et al.  Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma , 2007, Modern Pathology.

[45]  M. Nichols,et al.  CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer , 2006, International journal of cancer.

[46]  G. Donatini,et al.  Life-threatening hypercalcemia from a hepatocellular carcinoma secreting intact parathyroid hormone: localization by sestamibi single-photon emission computed tomographic imaging. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[47]  C. Laurell,et al.  Differential RNA Expression Profile by cDNA Microarray in Sporadic Primary Hyperparathyroidism (pHPT): Primary Parathyroid Hyperplasia versus Adenoma , 2006, World Journal of Surgery.

[48]  A. Behera,et al.  Cervical paraganglioma mimicking a parathyroid adenoma on Tc-99m sestamibi scintigraphy. , 2006, Clinical nuclear medicine.

[49]  D. Rimm,et al.  Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. , 2006, The Journal of clinical endocrinology and metabolism.

[50]  Y. Berland,et al.  Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[51]  N. Koszewski,et al.  Transactivation of the parathyroid hormone promoter by specificity proteins and the nuclear factor Y complex. , 2005, Endocrinology.

[52]  R. Arakaki,et al.  Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia , 2005, Endocrine.

[53]  K. Venkatasubbarao,et al.  Trichostatin A Induces Transforming Growth Factor β Type II Receptor Promoter Activity and Acetylation of Sp1 by Recruitment of PCAF/p300 to a Sp1·NF-Y Complex* , 2005, Journal of Biological Chemistry.

[54]  O. Kocher,et al.  Uncommon presentations of some common malignancies: Case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  T. Shiozawa,et al.  Ovarian non-small cell neuroendocrine carcinoma with paraneoplastic parathyroid hormone-related hypercalcemia. , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[56]  A. Nagasaka,et al.  Lung cancer associated with hypercalcemia induced by concurrently elevated parathyroid hormone and parathyroid hormone-related protein levels. , 2002, Metabolism: clinical and experimental.

[57]  J. Bollerslev,et al.  Parathyroid adenoma in a subject with familial hypocalciuric hypercalcemia: coincidence or causality? , 2002, The Journal of clinical endocrinology and metabolism.

[58]  Charles B. Hall,et al.  Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. , 2001, The Journal of clinical investigation.

[59]  M. Demay,et al.  Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice. , 2001, The Journal of clinical investigation.

[60]  G. Hendy,et al.  Mutations of the calcium‐sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia , 2000, Human mutation.

[61]  E. Brown,et al.  Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. , 2000, Endocrinology and metabolism clinics of North America.

[62]  Sudhaker Rao,et al.  Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis , 2000, Clinical endocrinology.

[63]  David J. Anderson,et al.  Genetic ablation of parathyroid glands reveals another source of parathyroid hormone , 2000, Nature.

[64]  F. Glorieux,et al.  Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. , 2000, Endocrinology.

[65]  W. Kuo,et al.  Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene , 2000, Nature Genetics.

[66]  Beretta,et al.  Calcium‐sensing receptor expression and signalling in human parathyroid adenomas and primary hyperplasia , 2000, Clinical endocrinology.

[67]  H. Ishizaka,et al.  Intact PTH-producing hepatocellular carcinoma treated by transcatheter arterial embolization , 1999, Abdominal Imaging.

[68]  A. Wolffe,et al.  Xenopus NF‐Y pre‐sets chromatin to potentiate p300 and acetylation‐responsive transcription from the Xenopus hsp70 promoter in vivo , 1998, The EMBO journal.

[69]  M. Tsuneyoshi,et al.  Hypercalcemia caused by ectopic production of parathyroid hormone in a patient with papillary adenocarcinoma of the thyroid gland. , 1998, The Journal of clinical endocrinology and metabolism.

[70]  Tatsuya Yoshizawa,et al.  Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning , 1997, Nature Genetics.

[71]  U. Feldt-Rasmussen,et al.  Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. , 1996, The Journal of clinical endocrinology and metabolism.

[72]  E. Ogata,et al.  The Interaction between Ku Antigen and REF1 Protein Mediates Negative Gene Regulation by Extracellular Calcium (*) , 1996, The Journal of Biological Chemistry.

[73]  S. Takeda,et al.  Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. , 1996, The Journal of clinical endocrinology and metabolism.

[74]  T. Okazaki,et al.  A redox factor protein, ref1, is involved in negative gene regulation by extracellular calcium. , 1994, The Journal of biological chemistry.

[75]  J. Bonjour,et al.  A thymoma as a cause of true ectopic hyperparathyroidism. , 1994, The Journal of clinical endocrinology and metabolism.

[76]  J. Seidman,et al.  Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism , 1993, Cell.

[77]  O. Clark,et al.  Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. , 1993, The Journal of clinical endocrinology and metabolism.

[78]  T. Schilling,et al.  Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. , 1993, The Journal of clinical endocrinology and metabolism.

[79]  E. Ogata,et al.  Conserved mechanism of negative gene regulation by extracellular calcium. Parathyroid hormone gene versus atrial natriuretic polypeptide gene. , 1992, The Journal of clinical investigation.

[80]  A. Arnold,et al.  Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. , 1990, The New England journal of medicine.

[81]  K. Yoshimoto,et al.  Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. , 1989, The Journal of clinical endocrinology and metabolism.

[82]  Y. Shakiba,et al.  Gene expression profiles of CYP24A1 and CYP27B1 in malignant and normal breast tissues. , 2017, Molecular medicine reports.

[83]  P. Friedlander,et al.  Ectopic secretion of parathyroid hormone in a neuroendocrine tumor: a case report and review of the literature. , 2011, International journal of clinical and experimental medicine.

[84]  Y. Abe,et al.  Severe hypercalcemia associated with hepatocellular carcinoma secreting intact parathyroid hormone: a case report. , 2011, Internal medicine.

[85]  Yuan Cheng,et al.  Ectopic production of parathyroid hormone in a patient with sporadic medullary thyroid cancer. , 2010, Endocrine journal.

[86]  D. Leprince,et al.  HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. , 2009, The international journal of biochemistry & cell biology.

[87]  R. Munasinghe,et al.  Hyperparathyroidism, hypercalcemia, and calcified brain metastatic lesions in a patient with small cell carcinoma demonstrating positive immunostain for parathyroid hormone. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[88]  R. Buller,et al.  Paraneoplastic hypercalcemia associated with adenosquamous carcinoma of the endometrium. , 1991, Gynecologic oncology.